Leading generics pharmaceutical company
‘A combination of FDA and TGA approved Ivermectin, Zinc and Doxycycline has shown positive results for COVID-19 and should be considered immediately to fight the pandemic’ says CDD Medical Director Professor Thomas Borody Australia’s The Centre for Digestive Disease (CDD) Medical Director Professor Thomas Borody MB, BS, BSc(Med), MD, PhD, DSc, FRACP,FACP,FACG, AGAF, says FDA […]
New research published in the British Journal of Pharmacology indicates that two currently available medications–an antifungal drug and an antidepressant–can effectively inhibit the virus that causes COVID-19 in laboratory cells. Investigators found that the antifungal itraconazole and the antidepressant fluoxetine each blocked the production of infectious SARS-CoV-2 virus in cell culture lab tests. When either […]
Encontre aqui Comprimidos de ivermectina aprovados pela FDA , fabricantes, fornecedores e exportadores de comprimidos de ivermectina na Índia. Obter contrato de fabricação para comprimidos de ivermectina , encontrar o melhor preço para comprimidos de ivermectina, medicamento genérico e versão genérica de comprimidos de ivermectina disponíveis com o melhor preço no fabricante aprovado pela GMP […]
Prednisone and other corticosteroids | The evidence is in. WHO says corticosteroids really do save lives of people critically ill with COVID-19
WHO chief on Monday urged for an increase in production of steroid dexamethasone to treat the critically-ill Covid-19 patients. Taj Pharmaceuticals, the well-known Dexamethasone Tablets API Manufacturer in India gives the assurance of high-quality and purity. The stringent quality-control ensure that every batch of the drug brings a consistent standard.
Dexamethasone is a type of corticosteroid medication manufactured by Taj Pharmaceuticals India. It is used in the treatment of many conditions, including COVID-19 respiratory side effects, rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, eye pain following eye surgery, and along with antibiotics in tuberculosis. In adrenocortical insufficiency, it should be used together with a medication that has greater mineralocorticoid effects such as fludrocortisone.[1] In preterm labor, it may be used to improve outcomes in the baby. It may be taken by mouth, as an injection into a muscle, or intravenously. The effects of dexamethasone are frequently seen within a day and last for about three days.
It’s likely you can, at least for some period of time. That is opening new opportunities for testing and treatment. #CoronaVirus #CoronaPrevention #Safety #tajpharmaCorona #CoronaSpread #IndiaFightsCorona #CoronavirusOutbreakindia #CoronavirusPandemic #StaySafeStayHome #IndiaFightsCoronavirus
The WHO said there’s no evidence serological tests can show whether a person has immunity or is no longer at risk of becoming reinfected. The World Health Organization issued a warning Friday about coronavirus testing, saying there’s no evidence serological tests can show whether a person has immunity or is no longer at risk of becoming reinfected. Bacteria & Viruses, coronavirus, COVID-19, Disease Info, Disease Trends, Drug Approvals, Drug News, Health & Disease, Health News, Industry News, Infectious Disease, Medical News, Press Release
ProPublica’s health reporter Caroline Chen explains what the conversation around asymptomatic coronavirus carriers is missing, and what we need to understand if we’re going to beat this nefarious virus together.
The FDA has approved an abbreviated new drug application for hydroxychloroquine sulfate tablets to address ongoing shortages of the drug sparked by its still unproven potential as a COVID-19 treatment. The application, submitted by Accord Healthcare, was approved on April 7. The approved indications are uncomplicated malaria due to Plasmodium falciparum, P. malariae, P. ovale, and P. vivax; chronic discoid lupus erythematosus and systemic lupus erythematosus in adults; and acute and chronic rheumatoid arthritis in adults.
